ML345 has effective concentration (EC50) value of 188 nM.[1]
ML345 is a cell penetrant, potent and moderately selective insulin degrading enzyme (IDE) inhibitor that targets Cys819 in IDE. IDE is involved in β-chain of insulin degradation and linked to β-amyloid degradation. Recent findings indicate that IDE inhibition is a valid strategy for diabetes mellitus type 2 (DMT2) treatment.
ML345 is a cell penetrant, potent and moderately selective insulin degrading enzyme (IDE) inhibitor.
Alzheimer's disease (AD) is characterised by the aggregation and deposition of amyloid-β (Aβ) peptides in the human brain. In age-related late-onset AD, deficient degradation and clearance, rather than enhanced production, of Aβ contributes to disease pathology. In the present study
The Cravatt group develops innovative technologies to understand enzyme roles in disease, focusing on activity-based protein profiling.
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.